{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:58:24Z","timestamp":1790366304023,"version":"4.1.0"},"publisher-location":"Berlin, Heidelberg","reference-count":181,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/164_2026_845","type":"book-chapter","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:58:51Z","timestamp":1790362731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of SGLT2 Inhibitors in Rodent Models of Diabetic Nephropathy"],"prefix":"10.1007","author":[{"given":"Aqsa","family":"Ashfaq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pautz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebru","family":"Arioglu-Inan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"845_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.biopha.2018.03.176","volume":"103","author":"AF Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab AF, Bamagous GA, Al-Harizy RM, ElSawy NA, Shahzad N, Ibrahim IA, Ghamdi SSA (2018) Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy. Biomed Pharmacother 103:59\u201366. https:\/\/doi.org\/10.1016\/j.biopha.2018.03.176","journal-title":"Biomed Pharmacother"},{"key":"845_CR2","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.19082\/1613","volume":"7","author":"S Abouzeid","year":"2015","unstructured":"Abouzeid S, Sherif N (2015) Role of alteration in Treg\/Th17 cells\u2019 balance in nephropathic patients with Type 2 diabetes mellitus. Electron Physician 7:1613\u20131618. https:\/\/doi.org\/10.19082\/1613","journal-title":"Electron Physician"},{"key":"845_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111624","volume":"139","author":"AS Ahmed","year":"2021","unstructured":"Ahmed AS, Mona MM, Abdel-Kareem MA, Elsisy RA (2021) SGLT2 inhibitor empagliflozin monotherapy alleviates renal oxidative stress in albino Wistar diabetic rats after myocardial infarction induction. Biomed Pharmacother 139:111624. https:\/\/doi.org\/10.1016\/j.biopha.2021.111624","journal-title":"Biomed Pharmacother"},{"key":"845_CR4","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429329635241016054513","volume":"17","author":"WA Alanazi","year":"2024","unstructured":"Alanazi WA, Alharbi T, Bin Anzan KM, Alyahiya MK, El-Nagar DM, Alanazi MM, Almutairi MM, Alhamami HN, Albogami AM, Mohany M (2024) The role of dapagliflozin in the modulation of hypothermia and renal injury caused by septic shock in euglycemic and hyperglycemic rat models. Curr Mol Pharmacol 17:e18761429329635. https:\/\/doi.org\/10.2174\/0118761429329635241016054513","journal-title":"Curr Mol Pharmacol"},{"key":"845_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2147\/jep.S522053","volume":"17","author":"AA Albanna","year":"2025","unstructured":"Albanna AA, Ibrahim DA, Shamsher AM, Al-Shawia MA, Halboup A (2025) The potential effect of dapagliflozin and liraglutide in attenuating cardio-renal injuries in diabetic rats. J Exp Pharmacol 17:467\u2013484. https:\/\/doi.org\/10.2147\/jep.S522053","journal-title":"J Exp Pharmacol"},{"key":"845_CR6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12933-018-0750-8","volume":"17","author":"AR Aroor","year":"2018","unstructured":"Aroor AR, Das NA, Carpenter AJ, Habibi J, Jia G, Ramirez-Perez FI, Martinez-Lemus L, Manrique-Acevedo CM, Hayden MR, Duta C, Nistala R, Mayoux E, Padilla J, Chandrasekar B, DeMarco VG (2018) Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. Cardiovasc Diabetol 17:108. https:\/\/doi.org\/10.1186\/s12933-018-0750-8","journal-title":"Cardiovasc Diabetol"},{"key":"845_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108503","volume":"249","author":"A Ashfaq","year":"2023","unstructured":"Ashfaq A, Meineck M, Pautz A, Arioglu-Inan E, Weinmann-Menke J, Michel MC (2023) A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy. Pharmacol Ther 249:e108503. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108503","journal-title":"Pharmacol Ther"},{"key":"845_CR8","doi-asserted-by":"publisher","first-page":"384","DOI":"10.22038\/ijbms.2019.31788.7651","volume":"22","author":"Z Ashrafi Jigheh","year":"2019","unstructured":"Ashrafi Jigheh Z, Ghorbani Haghjo A, Argani H, Roshangar L, Rashtchizadeh N, Sanajou D, Nazari Soltan Ahmad S, Rashedi J, Dastmalchi S, Mesgari Abbasi M (2019) Empagliflozin alleviates renal inflammation and oxidative stress in streptozotocin-induced diabetic rats partly by repressing HMGB1-TLR4 receptor axis. Iran J Basic Med Sci 22:384\u2013390. https:\/\/doi.org\/10.22038\/ijbms.2019.31788.7651","journal-title":"Iran J Basic Med Sci"},{"key":"845_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s12291-018-0790-6","volume":"35","author":"Z Ashrafi Jigheh","year":"2020","unstructured":"Ashrafi Jigheh Z, Ghorbani Haghjo A, Argani H, Roshangar L, Rashtchizadeh N, Sanajou D, Nazari Soltan Ahmad S, Rashedi J, Dastmalchi S, Mesgari Abbasi M (2020) Empagliflozin attenuates renal and urinary markers of tubular epithelial cell injury in streptozotocin-induced diabetic rats. Indian J Clin Biochem 35:109\u2013114. https:\/\/doi.org\/10.1007\/s12291-018-0790-6","journal-title":"Indian J Clin Biochem"},{"key":"845_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.967822","volume":"13","author":"Z Bai","year":"2022","unstructured":"Bai Z, Xie T, Liu T, Chen Z, Yu L, Zhang C, Luo J, Chen L, Zhao X, Xiao Y (2022) An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy. Front Endocrinol (Lausanne) 13:967822. https:\/\/doi.org\/10.3389\/fendo.2022.967822","journal-title":"Front Endocrinol (Lausanne)"},{"key":"845_CR11","doi-asserted-by":"publisher","first-page":"14754","DOI":"10.1038\/s41598-019-51343-1","volume":"9","author":"R Bessho","year":"2019","unstructured":"Bessho R, Takiyama Y, Takiyama T, Kitsunai H, Takeda Y, Sakagami H, Ota T (2019) Hypoxia-inducible factor-1\u03b1 is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. Sci Rep 9:14754. https:\/\/doi.org\/10.1038\/s41598-019-51343-1","journal-title":"Sci Rep"},{"key":"845_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10557-018-6778-x","volume":"32","author":"Y Birnbaum","year":"2018","unstructured":"Birnbaum Y, Bajaj M, Yang HC, Ye Y (2018) Combined SGLT2 and DPP4 inhibition reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of dDiabetic nephropathy in mice with type 2 diabetes. Cardiovasc Drugs Ther 32:135\u2013145. https:\/\/doi.org\/10.1007\/s10557-018-6778-x","journal-title":"Cardiovasc Drugs Ther"},{"key":"845_CR13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s10557-021-07222-x","volume":"36","author":"Y Birnbaum","year":"2022","unstructured":"Birnbaum Y, Chen H, Tran D, Nylander S, Ye Y (2022) Ticagrelor and dapagliflozin have additive effects in ameliorating diabetic nephropathy in mice with type-2 diabetes mellitus. Cardiovasc Drugs Ther 36:829\u2013840. https:\/\/doi.org\/10.1007\/s10557-021-07222-x","journal-title":"Cardiovasc Drugs Ther"},{"key":"845_CR14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41419-020-2544-7","volume":"11","author":"T Cai","year":"2020","unstructured":"Cai T, Ke Q, Fang Y, Wen P, Chen H, Yuan Q, Luo J, Zhang Y, Sun Q, Lv Y, Zen K, Jiang L, Zhou Y, Yang J (2020) Sodium-glucose cotransporter 2 inhibition suppresses HIF-1\u03b1-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice. Cell Death Dis 11:390. https:\/\/doi.org\/10.1038\/s41419-020-2544-7","journal-title":"Cell Death Dis"},{"key":"845_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1205834","volume":"14","author":"A Cai","year":"2023","unstructured":"Cai A, Shen J, Yang X, Shao X, Gu L, Mou S, Che X (2023) Dapagliflozin alleviates renal inflammation and protects against diabetic kidney diseases, both dependent and independent of blood glucose levels. Front Immunol 14:1205834. https:\/\/doi.org\/10.3389\/fimmu.2023.1205834","journal-title":"Front Immunol"},{"key":"845_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-025-05688-8","volume":"82","author":"X Cai","year":"2025","unstructured":"Cai X, Cao H, Wang M, Yu P, Liang X, Liang H, Xu F, Cai M (2025) SGLT2 inhibitor empagliflozin ameliorates tubulointerstitial fibrosis in DKD by downregulating renal tubular PKM2. Cell Mol Life Sci 82:159. https:\/\/doi.org\/10.1007\/s00018-025-05688-8","journal-title":"Cell Mol Life Sci"},{"key":"845_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.729334","volume":"12","author":"DY Chang","year":"2021","unstructured":"Chang DY, Li XQ, Chen M, Zhao MH (2021) Dapagliflozin ameliorates diabetic kidney disease via upregulating Crry and alleviating complement over-activation in db\/db mice. Front Pharmacol 12:729334. https:\/\/doi.org\/10.3389\/fphar.2021.729334","journal-title":"Front Pharmacol"},{"key":"845_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.trsl.2024.12.005","volume":"277","author":"SY Chang","year":"2025","unstructured":"Chang SY, Liao MC, Miyata KN, Pang Y, Zhao XP, Peng J, Rivard A, Ingelfinger JR, Chan JSD, Zhang SL (2025) Canagliflozin inhibits hedgehog interacting protein (Hhip) induction of tubulopathy in diabetic Akita mice. Transl Res 277:13\u201326. https:\/\/doi.org\/10.1016\/j.trsl.2024.12.005","journal-title":"Transl Res"},{"key":"845_CR19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.amjms.2016.08.015","volume":"352","author":"L Chen","year":"2016","unstructured":"Chen L, LaRocque LM, Efe O, Wang J, Sands JM, Klein JD (2016) Effect of dapagliflozin treatment on fluid and electrolyte balance in diabetic rats. Am J Med Sci 352:517\u2013523. https:\/\/doi.org\/10.1016\/j.amjms.2016.08.015","journal-title":"Am J Med Sci"},{"key":"845_CR20","doi-asserted-by":"publisher","first-page":"729","DOI":"10.7150\/ijms.69031","volume":"19","author":"PJ Chi","year":"2022","unstructured":"Chi PJ, Lee CJ, Hsieh YJ, Lu CW, Hsu BG (2022) Dapagliflozin ameliorates lipopolysaccharide related acute kidney injury in mice with streptozotocin-induced diabetes mellitus. Int J Med Sci 19:729\u2013739. https:\/\/doi.org\/10.7150\/ijms.69031","journal-title":"Int J Med Sci"},{"key":"845_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.00271","volume":"10","author":"S Chung","year":"2019","unstructured":"Chung S, Kim S, Son M, Kim M, Koh ES, Shin SJ, Ko SH, Kim HS (2019) Empagliflozin contributes to polyuria via regulation of sodium transporters and water channels in diabetic rat kidneys. Front Physiol 10:271. https:\/\/doi.org\/10.3389\/fphys.2019.00271","journal-title":"Front Physiol"},{"key":"845_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-025-01670-0","volume":"24","author":"HH Chung","year":"2025","unstructured":"Chung HH, Tseng CJ, Cheng PW (2025) The multifaceted modulations by dapagliflozin in preventing hyperglycemia-induced diabetic nephropathy through glucose transporters and PPAR\u03b1. J Diabetes Metab Disord 24:154. https:\/\/doi.org\/10.1007\/s40200-025-01670-0","journal-title":"J Diabetes Metab Disord"},{"key":"845_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-84487-w","volume":"15","author":"A Cinakova","year":"2025","unstructured":"Cinakova A, Vavrincova-Yaghi D, Krenek P, Klimas J, Kralova E (2025) Combination of dapagliflozin and pioglitazone lacks superiority against monotherapy in streptozotocin-induced nephropathy. Sci Rep 15:1464. https:\/\/doi.org\/10.1038\/s41598-024-84487-w","journal-title":"Sci Rep"},{"key":"845_CR24","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1007\/s00210-025-04613-x","volume":"399","author":"A Cinakova","year":"2026","unstructured":"Cinakova A, Vavrincova-Yaghi D, Vavrinec D, Krenek P, Klimas J, Kralova E (2026) Combined dapagliflozin and pioglitazone therapy in diabetic nephropathy: no added benefit beyond monotherapy in inflammation and fibrosis. Naunyn Schmiedeberg\u2019s Arch Pharmacol 399:3001\u20133015. https:\/\/doi.org\/10.1007\/s00210-025-04613-x","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"845_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2022.111811","volume":"560","author":"MA Cornejo","year":"2023","unstructured":"Cornejo MA, Jardines E, Nishiyama A, Nakano D, Ortiz RM (2023) Simultaneous SGLT2 inhibition and caloric restriction improves insulin resistance and kidney function in OLETF rats. Mol Cell Endocrinol 560:111811. https:\/\/doi.org\/10.1016\/j.mce.2022.111811","journal-title":"Mol Cell Endocrinol"},{"key":"845_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24109043","volume":"24","author":"R Corremans","year":"2023","unstructured":"Corremans R, Vervaet BA, Dams G, D\u2019Haese PC, Verhulst A (2023) Metformin and canagliflozin are equally renoprotective in diabetic kidney disease but have no synergistic effect. Int J Mol Sci 24:9043. https:\/\/doi.org\/10.3390\/ijms24109043","journal-title":"Int J Mol Sci"},{"key":"845_CR27","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1097\/hjh.0000000000003633","volume":"42","author":"EO Cruz-L\u00f3pez","year":"2024","unstructured":"Cruz-L\u00f3pez EO, Ye D, Stolk DG, Clahsen-van Groningen MC, van Veghel R, Garrelds IM, Poglitsch M, Domenig O, Alipour Symakani RS, Merkus D, Verdonk K, Jan Danser AH (2024) Combining renin-angiotensin system blockade and sodium-glucose cotransporter-2 inhibition in experimental diabetes results in synergistic beneficial effects. J Hypertens 42:883\u2013892. https:\/\/doi.org\/10.1097\/hjh.0000000000003633","journal-title":"J Hypertens"},{"key":"845_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115840","volume":"168","author":"J Da","year":"2023","unstructured":"Da J, Xu Y, Tan Y, Zhang J, Yu J, Zhao J, Da Q, Yu F, Zha Y (2023) Central administration of dapagliflozin alleviates a hypothalamic neuroinflammatory signature and changing tubular lipid metabolism in type 2 diabetic nephropathy by upregulating MCPIP1. Biomed Pharmacother 168:115840. https:\/\/doi.org\/10.1016\/j.biopha.2023.115840","journal-title":"Biomed Pharmacother"},{"key":"845_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14711","volume":"38","author":"LF Daniels Gatward","year":"2021","unstructured":"Daniels Gatward LF, Kennard MR, Smith LIF, King AJF (2021) The use of mice in diabetes research: the impact of physiological characteristics, choice of model and husbandry practices. Diabet Med 38:e14711. https:\/\/doi.org\/10.1111\/dme.14711","journal-title":"Diabet Med"},{"key":"845_CR30","doi-asserted-by":"publisher","unstructured":"Dia B, Alkhansa S, Njeim R, Al Moussawi S, Farhat T, Haddad A, Riachi ME, Nawfal R, Azar WS, Eid AA (2023) SGLT2 inhibitor-dapagliflozin attenuates diabetes-induced renal injury by regulating inflammation through a CYP4A\/20-HETE signaling mechanism. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15030965","DOI":"10.3390\/pharmaceutics15030965"},{"key":"845_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251135","volume":"16","author":"A Domon","year":"2021","unstructured":"Domon A, Katayama K, Sato T, Tochigi Y, Tazaki H, Suzuki H (2021) Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK). PLoS One 16:e0251135. https:\/\/doi.org\/10.1371\/journal.pone.0251135","journal-title":"PLoS One"},{"key":"845_CR32","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/fcp.12765","volume":"36","author":"AMH El Medany","year":"2022","unstructured":"El Medany AMH, Hammadi SHM, Khalifa HM, Ghazala RA, Zakaria Mohammed HS (2022) The vascular impact of dapagliflozin, liraglutide, and atorvastatin alone or in combinations in type 2 diabetic rat model. Fundam Clin Pharmacol 36:731\u2013741. https:\/\/doi.org\/10.1111\/fcp.12765","journal-title":"Fundam Clin Pharmacol"},{"key":"845_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119018","volume":"280","author":"SK Elkazzaz","year":"2021","unstructured":"Elkazzaz SK, Khodeer DM, El Fayoumi HM, Moustafa YM (2021) Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; inflammation, angiogenesis and apoptosis. Life Sci 280:119018. https:\/\/doi.org\/10.1016\/j.lfs.2021.119018","journal-title":"Life Sci"},{"key":"845_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175521","volume":"942","author":"RS Farias","year":"2023","unstructured":"Farias RS, Silva-Aguiar RP, Teixeira DE, Gomes CP, Pinheiro AAS, Peruchetti DB, Caruso-Neves C (2023) Inhibition of SGLT2 co-transporter by dapagliflozin ameliorates tubular proteinuria and tubule-interstitial injury at the early stage of diabetic kidney disease. Eur J Pharmacol 942:175521. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175521","journal-title":"Eur J Pharmacol"},{"key":"845_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108409","volume":"37","author":"B Feng","year":"2023","unstructured":"Feng B, Yang F, Liu J, Sun Q, Meng R, Zhu D (2023a) Amelioration of diabetic kidney injury with dapagliflozin is associated with suppressing renal HMGB1 expression and restoring autophagy in obese mice. J Diabetes Complicat 37:108409. https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108409","journal-title":"J Diabetes Complicat"},{"key":"845_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121671","volume":"322","author":"L Feng","year":"2023","unstructured":"Feng L, Chen Y, Li N, Yang X, Zhou L, Li H, Wang T, Xie M, Liu H (2023b) Dapagliflozin delays renal fibrosis in diabetic kidney disease by inhibiting YAP\/TAZ activation. Life Sci 322:121671. https:\/\/doi.org\/10.1016\/j.lfs.2023.121671","journal-title":"Life Sci"},{"key":"845_CR37","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bbrc.2022.10.034","volume":"635","author":"H Fujita","year":"2022","unstructured":"Fujita H, Otomo H, Takahashi Y, Yamada Y (2022) Dual inhibition of SGLT2 and DPP-4 promotes natriuresis and improves glomerular hemodynamic abnormalities in KK\/Ta-Ins2(Akita) mice with progressive diabetic kidney disease. Biochem Biophys Res Commun 635:84\u201391. https:\/\/doi.org\/10.1016\/j.bbrc.2022.10.034","journal-title":"Biochem Biophys Res Commun"},{"key":"845_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/srep26428","volume":"6","author":"LA Gallo","year":"2016","unstructured":"Gallo LA, Ward MS, Fotheringham AK, Zhuang A, Borg DJ, Flemming NB, Harvie BM, Kinneally TL, Yeh SM, McCarthy DA, Koepsell H, Vallon V, Pollock C, Panchapakesan U, Forbes JM (2016) Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db\/db mice. Sci Rep 6:26428. https:\/\/doi.org\/10.1038\/srep26428","journal-title":"Sci Rep"},{"key":"845_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2023.112139","volume":"582","author":"T Gan","year":"2024","unstructured":"Gan T, Wang Q, Song Y, Shao M, Zhao Y, Guo F, Wei F, Fan X, Zhang W, Luo Y, Chen D, Wang S, Qin G (2024) Canagliflozin improves fatty acid oxidation and ferroptosis of renal tubular epithelial cells via FOXA1-CPT1A axis in diabetic kidney disease. Mol Cell Endocrinol 582:112139. https:\/\/doi.org\/10.1016\/j.mce.2023.112139","journal-title":"Mol Cell Endocrinol"},{"key":"845_CR40","doi-asserted-by":"publisher","first-page":"F317","DOI":"10.1152\/ajprenal.00145.2014","volume":"307","author":"F Gembardt","year":"2014","unstructured":"Gembardt F, Bartaun C, Jarzebska N, Mayoux E, Todorov VT, Hohenstein B, Hugo C (2014) The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob\/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol 307:F317\u2013F325. https:\/\/doi.org\/10.1152\/ajprenal.00145.2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"845_CR41","doi-asserted-by":"publisher","unstructured":"Gholam MF, Liu LP, Searcy LA, Denslow ND, Alli AA (2023) Dapagliflozin treatment augments bioactive phosphatidylethanolamine concentrations in kidney cortex membrane fractions of hypertensive diabetic db\/db mice and alters the density of lipid rafts in mouse proximal tubule cells. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24021408","DOI":"10.3390\/ijms24021408"},{"key":"845_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00412","volume":"9","author":"E Han","year":"2018","unstructured":"Han E, Shin E, Kim G, Lee JY, Lee YH, Lee BW, Kang ES, Cha BS (2018) Combining SGLT2 inhibition with a thiazolidinedione additively attenuate the very early phase of diabetic nephropathy progression in type 2 diabetes melllitus. Front Endocrinol (Lausanne) 9:412. https:\/\/doi.org\/10.3389\/fendo.2018.00412","journal-title":"Front Endocrinol (Lausanne)"},{"key":"845_CR43","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14890","volume":"9","author":"GMT Hare","year":"2021","unstructured":"Hare GMT, Zhang Y, Chin K, Thai K, Jacobs E, Cazorla-Bak MP, Nghiem L, Wilson DF, Vinogradov SA, Connelly KA, Mazer CD, Evans RG, Gilbert RE (2021) Impact of sodium glucose linked cotransporter-2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus. Physiol Rep 9:e14890. https:\/\/doi.org\/10.14814\/phy2.14890","journal-title":"Physiol Rep"},{"key":"845_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.239","volume":"4","author":"T Hatanaka","year":"2016","unstructured":"Hatanaka T, Ogawa D, Tachibana H, Eguchi J, Inoue T, Yamada H, Takei K, Makino H, Wada J (2016) Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice. Pharmacol Res Perspect 4:e00239. https:\/\/doi.org\/10.1002\/prp2.239","journal-title":"Pharmacol Res Perspect"},{"key":"845_CR45","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sj\u00f6str\u00f6m CD, Toto RD, Langkilde AM, Wheeler DC (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"845_CR46","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.3748\/wjg.v26.i23.3225","volume":"26","author":"LY Herat","year":"2020","unstructured":"Herat LY, Ward NC, Magno AL, Rakoczy EP, Kiuchi MG, Schlaich MP, Matthews VB (2020) Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice. World J Gastroenterol 26:3225\u20133235. https:\/\/doi.org\/10.3748\/wjg.v26.i23.3225","journal-title":"World J Gastroenterol"},{"key":"845_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107260","volume":"26","author":"LY Herat","year":"2023","unstructured":"Herat LY, Matthews JR, Hibbs M, Rakoczy EP, Schlaich MP, Matthews VB (2023) SGLT1\/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes. iScience 26:107260. https:\/\/doi.org\/10.1016\/j.isci.2023.107260","journal-title":"iScience"},{"key":"845_CR48","doi-asserted-by":"publisher","first-page":"F1017","DOI":"10.1152\/ajprenal.00021.2020","volume":"318","author":"J Hodrea","year":"2020","unstructured":"Hodrea J, Balogh DB, Hosszu A, Lenart L, Besztercei B, Koszegi S, Sparding N, Genovese F, Wagner LJ, Szabo AJ, Fekete A (2020) Reduced O-GlcNAcylation and tubular hypoxia contribute to the antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic kidney. Am J Physiol Renal Physiol 318:F1017\u2013f1029. https:\/\/doi.org\/10.1152\/ajprenal.00021.2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"845_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00441","volume":"10","author":"F Huang","year":"2019","unstructured":"Huang F, Zhao Y, Wang Q, Hillebrands JL, van den Born J, Ji L, An T, Qin G (2019) Dapagliflozin attenuates renal tubulointerstitial fibrosis associated with type 1 diabetes by regulating STAT1\/TGF\u03b21 signaling. Front Endocrinol (Lausanne) 10:441. https:\/\/doi.org\/10.3389\/fendo.2019.00441","journal-title":"Front Endocrinol (Lausanne)"},{"key":"845_CR50","doi-asserted-by":"publisher","unstructured":"Huang CC, Chou CA, Chen WY, Yang JL, Lee WC, Chen JB, Lee CT, Li LC (2021) Empagliflozin ameliorates free fatty acid induced-lipotoxicity in renal proximal tubular cells via the PPAR\u03b3\/CD36 pathway in obese mice. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms222212408","DOI":"10.3390\/ijms222212408"},{"key":"845_CR51","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9735555","volume":"2022","author":"B Huang","year":"2022","unstructured":"Huang B, Wen W, Ye S (2022a) Dapagliflozin ameliorates renal tubular ferroptosis in diabetes via SLC40A1 stabilization. Oxidative Med Cell Longev 2022:9735555. https:\/\/doi.org\/10.1155\/2022\/9735555","journal-title":"Oxidative Med Cell Longev"},{"key":"845_CR52","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1124\/jpet.121.000956","volume":"380","author":"D Huang","year":"2022","unstructured":"Huang D, Ju F, Du L, Liu T, Zuo Y, Abbott GW, Hu Z (2022b) Empagliflozin protects against pulmonary ischemia\/reperfusion injury via an extracellular signal-regulated kinases 1 and 2-dependent mechanism. J Pharmacol Exp Ther 380:230\u2013241. https:\/\/doi.org\/10.1124\/jpet.121.000956","journal-title":"J Pharmacol Exp Ther"},{"key":"845_CR53","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1097\/fjc.0000000000001268","volume":"79","author":"X Huang","year":"2022","unstructured":"Huang X, Guo X, Yan G, Zhang Y, Yao Y, Qiao Y, Wang D, Chen G, Zhang W, Tang C, Cao F (2022c) Dapagliflozin attenuates contrast-induced acute kidney injury by regulating the HIF-1\u03b1\/HE4\/NF-\u03baB pathway. J Cardiovasc Pharmacol 79:904\u2013913. https:\/\/doi.org\/10.1097\/fjc.0000000000001268","journal-title":"J Cardiovasc Pharmacol"},{"key":"845_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117589","volume":"180","author":"J Huang","year":"2024","unstructured":"Huang J, Liu Y, Shi M, Zhang X, Zhong Y, Guo S, Ma Y, Pan L, Yang F, Wang Y (2024) Empagliflozin attenuating renal interstitial fibrosis in diabetic kidney disease by inhibiting lymphangiogenesis and lymphatic endothelial-to-mesenchymal transition via the VEGF-C\/VEGFR3 pathway. Biomed Pharmacother 180:117589. https:\/\/doi.org\/10.1016\/j.biopha.2024.117589","journal-title":"Biomed Pharmacother"},{"key":"845_CR55","doi-asserted-by":"publisher","first-page":"F48","DOI":"10.1152\/ajprenal.00065.2024","volume":"328","author":"S Hummelgaard","year":"2025","unstructured":"Hummelgaard S, Hvid H, Birn H, Glerup S, Tom N, Bilgin M, Kirchhoff JE, Weyer K (2025) Lack of renoprotective effects by long-term PCSK9 and SGLT2 inhibition using alirocumab and empagliflozin in obese ZSF1 rats. Am J Physiol Renal Physiol 328:F48\u2013f67. https:\/\/doi.org\/10.1152\/ajprenal.00065.2024","journal-title":"Am J Physiol Renal Physiol"},{"key":"845_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-019-0454-6","volume":"11","author":"MK Inoue","year":"2019","unstructured":"Inoue MK, Matsunaga Y, Nakatsu Y, Yamamotoya T, Ueda K, Kushiyama A, Sakoda H, Fujishiro M, Ono H, Iwashita M, Sano T, Nishimura F, Morii K, Sasaki K, Masaki T, Asano T (2019) Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice. Diabetol Metab Syndr 11:57. https:\/\/doi.org\/10.1186\/s13098-019-0454-6","journal-title":"Diabetol Metab Syndr"},{"key":"845_CR57","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1177\/1479164116657304","volume":"13","author":"Y Ishibashi","year":"2016","unstructured":"Ishibashi Y, Matsui T, Yamagishi SI (2016) Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy\/Ta mice, obese and type 2 diabetic animals. Diab Vasc Dis Res 13:438\u2013441. https:\/\/doi.org\/10.1177\/1479164116657304","journal-title":"Diab Vasc Dis Res"},{"key":"845_CR58","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1111\/dom.13441","volume":"20","author":"K Jaikumkao","year":"2018","unstructured":"Jaikumkao K, Pongchaidecha A, Chueakula N, Thongnak LO, Wanchai K, Chatsudthipong V, Chattipakorn N, Lungkaphin A (2018) Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats. Diabetes Obes Metab 20:2617\u20132626. https:\/\/doi.org\/10.1111\/dom.13441","journal-title":"Diabetes Obes Metab"},{"key":"845_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2023.166912","volume":"1870","author":"K Jaikumkao","year":"2024","unstructured":"Jaikumkao K, Thongnak L, Htun KT, Pengrattanachot N, Phengpol N, Sutthasupha P, Promsan S, Montha N, Sriburee S, Kothan S, Lungkaphin A (2024) Dapagliflozin and metformin in combination ameliorates diabetic nephropathy by suppressing oxidative stress, inflammation, and apoptosis and activating autophagy in diabetic rats. Biochim Biophys Acta Mol basis Dis 1870:166912. https:\/\/doi.org\/10.1016\/j.bbadis.2023.166912","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"key":"845_CR60","doi-asserted-by":"publisher","first-page":"F17","DOI":"10.1152\/ajprenal.00184.2025","volume":"330","author":"M Jensen","year":"2026","unstructured":"Jensen M, Thiel S, Hansen SWK, Palarasah Y, Svenningsen P, Jensen BL (2026) SGLT-2 inhibitors attenuate pattern-recognition molecules collectin kidney 1 and mannose-binding lectin in kidney and liver in mice with diabetes. Am J Physiol Renal Physiol 330:F17\u2013f31. https:\/\/doi.org\/10.1152\/ajprenal.00184.2025","journal-title":"Am J Physiol Renal Physiol"},{"key":"845_CR61","doi-asserted-by":"publisher","first-page":"613","DOI":"10.4196\/kjpp.24.424","volume":"29","author":"DS Jeong","year":"2025","unstructured":"Jeong DS, Ko SM, Lee JY, Han HJ, Lee Y, Lee WS, Lee EA, Son WC, Shin J (2025) Tie2 activator 4E2 ameliorates diabetic nephropathy and synergizes with dapagliflozin in a mouse model. Korean J Physiol Pharmacol 29:613\u2013623. https:\/\/doi.org\/10.4196\/kjpp.24.424","journal-title":"Korean J Physiol Pharmacol"},{"key":"845_CR62","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1159\/000487783","volume":"45","author":"Y Jia","year":"2018","unstructured":"Jia Y, He J, Wang L, Su L, Lei L, Huang W, Geng X, Zhang S, Meng X, Zhou H, Yang B (2018) Dapagliflozin aggravates renal injury via promoting gluconeogenesis in db\/db mice. Cell Physiol Biochem 45:1747\u20131758. https:\/\/doi.org\/10.1159\/000487783","journal-title":"Cell Physiol Biochem"},{"key":"845_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2024.108687","volume":"38","author":"M Jiang","year":"2024","unstructured":"Jiang M, Yang Z, Lyu L, Shi M (2024) Dapagliflozin attenuates renal fibrosis by suppressing angiotensin II\/TGF\u03b2 signaling in diabetic mice. J Diabetes Complicat 38:108687. https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108687","journal-title":"J Diabetes Complicat"},{"key":"845_CR64","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1111\/ajt.14316","volume":"17","author":"J Jin","year":"2017","unstructured":"Jin J, Jin L, Luo K, Lim SW, Chung BH, Yang CW (2017) Effect of empagliflozin on tacrolimus-induced pancreas Islet dysfunction and renal injury. Am J Transplant 17:2601\u20132616. https:\/\/doi.org\/10.1111\/ajt.14316","journal-title":"Am J Transplant"},{"key":"845_CR65","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1113\/ep090849","volume":"108","author":"NK Jones","year":"2023","unstructured":"Jones NK, Costello HM, Monaghan MT, Stewart K, Binnie D, Marks J, Bailey MA, Culshaw GJ (2023) Sodium-glucose cotransporter 2 inhibition does not improve the acute pressure natriuresis response in rats with type 1 diabetes. Exp Physiol 108:480\u2013490. https:\/\/doi.org\/10.1113\/ep090849","journal-title":"Exp Physiol"},{"key":"845_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22229-5","volume":"8","author":"M Kamezaki","year":"2018","unstructured":"Kamezaki M, Kusaba T, Komaki K, Fushimura Y, Watanabe N, Ikeda K, Kitani T, Yamashita N, Uehara M, Kirita Y, Shiotsu Y, Sakai R, Fukuda T, Yamazaki M, Fukui M, Matoba S, Tamagaki K (2018) Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice. Sci Rep 8:4029. https:\/\/doi.org\/10.1038\/s41598-018-22229-5","journal-title":"Sci Rep"},{"key":"845_CR67","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1161\/circulationaha.118.037418","volume":"140","author":"K Kidokoro","year":"2019","unstructured":"Kidokoro K, Cherney DZI, Bozovic A, Nagasu H, Satoh M, Kanda E, Sasaki T, Kashihara N (2019) Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging. Circulation 140:303\u2013315. https:\/\/doi.org\/10.1161\/circulationaha.118.037418","journal-title":"Circulation"},{"key":"845_CR68","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/dom.13577","volume":"21","author":"JH Kim","year":"2019","unstructured":"Kim JH, Lee M, Kim SH, Kim SR, Lee BW, Kang ES, Cha BS, Cho JW, Lee YH (2019) Sodium-glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter-organ crosstalk. Diabetes Obes Metab 21:801\u2013811. https:\/\/doi.org\/10.1111\/dom.13577","journal-title":"Diabetes Obes Metab"},{"key":"845_CR69","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/dom.13905","volume":"22","author":"JH Kim","year":"2020","unstructured":"Kim JH, Ko HY, Wang HJ, Lee H, Yun M, Kang ES (2020) Effect of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on gluconeogenesis in proximal renal tubules. Diabetes Obes Metab 22:373\u2013382. https:\/\/doi.org\/10.1111\/dom.13905","journal-title":"Diabetes Obes Metab"},{"key":"845_CR70","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1111\/dom.14503","volume":"23","author":"MN Kim","year":"2021","unstructured":"Kim MN, Moon JH, Cho YM (2021) Sodium-glucose cotransporter-2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body-induced NRF2 activation. Diabetes Obes Metab 23:2561\u20132571. https:\/\/doi.org\/10.1111\/dom.14503","journal-title":"Diabetes Obes Metab"},{"key":"845_CR71","doi-asserted-by":"publisher","first-page":"F68","DOI":"10.1152\/ajprenal.00231.2024","volume":"328","author":"YC Kim","year":"2025","unstructured":"Kim YC, Das V, Kanoo S, Yao H, Stanford SM, Bottini N, Karihaloo A, Vallon V (2025) Transcriptomics of SGLT2-positive early proximal tubule segments in mice: response to type 1 diabetes, SGLT1\/2 inhibition, or GLP1 receptor agonism. Am J Physiol Renal Physiol 328:F68\u2013f81. https:\/\/doi.org\/10.1152\/ajprenal.00231.2024","journal-title":"Am J Physiol Renal Physiol"},{"key":"845_CR72","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/jdi.13009","volume":"10","author":"Y Kimura","year":"2019","unstructured":"Kimura Y, Kuno A, Tanno M, Sato T, Ohno K, Shibata S, Nakata K, Sugawara H, Abe K, Igaki Y, Yano T, Miki T, Miura T (2019) Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats. J Diabetes Investig 10:933\u2013946. https:\/\/doi.org\/10.1111\/jdi.13009","journal-title":"J Diabetes Investig"},{"key":"845_CR73","doi-asserted-by":"publisher","first-page":"596","DOI":"10.4239\/wjd.v11.i12.596","volume":"11","author":"VV Klimontov","year":"2020","unstructured":"Klimontov VV, Korbut AI, Taskaeva IS, Bgatova NP, Dashkin MV, Orlov NB, Khotskina AS, Zavyalov EL, Klein T (2020) Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db\/db diabetic mice. World J Diabetes 11:596\u2013610. https:\/\/doi.org\/10.4239\/wjd.v11.i12.596","journal-title":"World J Diabetes"},{"key":"845_CR74","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1124\/jpet.113.203869","volume":"345","author":"N Kojima","year":"2013","unstructured":"Kojima N, Williams JM, Takahashi T, Miyata N, Roman RJ (2013) Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther 345:464\u2013472. https:\/\/doi.org\/10.1124\/jpet.113.203869","journal-title":"J Pharmacol Exp Ther"},{"key":"845_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108994","volume":"9","author":"MG Komala","year":"2014","unstructured":"Komala MG, Gross S, Mudaliar H, Huang C, Pegg K, Mather A, Shen S, Pollock CA, Panchapakesan U (2014) Inhibition of kidney proximal tubular glucose reabsorption doesn ot prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice. PLoS One 9:e108994. https:\/\/doi.org\/10.1371\/journal.pone.0108994","journal-title":"PLoS One"},{"key":"845_CR76","doi-asserted-by":"publisher","unstructured":"Korbut AI, Taskaeva IS, Bgatova NP, Muraleva NA, Orlov NB, Dashkin MV, Khotskina AS, Zavyalov EL, Konenkov VI, Klein T, Klimontov VV (2020) SGLT2 inhibitor empagliflozin and DPP4 inhibitor linagliptin reactivate glomerular autophagy in db\/db mice, a model of type 2 diabetes. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21082987","DOI":"10.3390\/ijms21082987"},{"key":"845_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.982722","volume":"13","author":"H Kroeger","year":"2022","unstructured":"Kroeger H, Kessel F, Sradnick J, Todorov V, Gembardt F, Hugo C (2022) Intravital imaging of hemodynamic glomerular effects of enalapril or\/and empagliflozin in STZ-diabetic mice. Front Physiol 13:982722. https:\/\/doi.org\/10.3389\/fphys.2022.982722","journal-title":"Front Physiol"},{"key":"845_CR78","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1038\/s41598-020-64380-y","volume":"10","author":"A Kuno","year":"2020","unstructured":"Kuno A, Kimura Y, Mizuno M, Oshima H, Sato T, Moniwa N, Tanaka M, Yano T, Tanno M, Miki T, Miura T (2020) Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats. Sci Rep 10:7238. https:\/\/doi.org\/10.1038\/s41598-020-64380-y","journal-title":"Sci Rep"},{"key":"845_CR79","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4093\/dmj.2017.0095","volume":"42","author":"KA Lee","year":"2018","unstructured":"Lee KA, Jin HY, Lee NY, Kim YJ, Park TS (2018) Effect of empagliflozin, a selective sodium-glucose cotransporter 2 inhibitor, on kidney and peripheral nerves in streptozotocin-induced diabetic rats. Diabetes Metab J 42:338\u2013342. https:\/\/doi.org\/10.4093\/dmj.2017.0095","journal-title":"Diabetes Metab J"},{"key":"845_CR80","doi-asserted-by":"publisher","first-page":"F767","DOI":"10.1152\/ajprenal.00565.2018","volume":"317","author":"YH Lee","year":"2019","unstructured":"Lee YH, Kim SH, Kang JM, Heo JH, Kim DJ, Park SH, Sung M, Kim J, Oh J, Yang DH, Lee SH, Lee SY (2019) Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. Am J Physiol Renal Physiol 317:F767\u2013F780. https:\/\/doi.org\/10.1152\/ajprenal.00565.2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"845_CR81","doi-asserted-by":"publisher","unstructured":"Li J, Liu H, Takagi S, Nitta K, Kitada M, Srivastava SP, Takagaki Y, Kanasaki K, Koya D (2020a) Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.129034","DOI":"10.1172\/jci.insight.129034"},{"key":"845_CR82","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1002\/2211-5463.13014","volume":"10","author":"Z Li","year":"2020","unstructured":"Li Z, Murakoshi M, Ichikawa S, Koshida T, Adachi E, Suzuki C, Ueda S, Gohda T, Suzuki Y (2020b) The sodium-glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice. FEBS Open Bio 10:2761\u20132770. https:\/\/doi.org\/10.1002\/2211-5463.13014","journal-title":"FEBS Open Bio"},{"key":"845_CR83","doi-asserted-by":"publisher","first-page":"7667","DOI":"10.21037\/qims-23-409","volume":"13","author":"Y Li","year":"2023","unstructured":"Li Y, Liu ZS, Wei R, Liu ZW, Guo LX, Ren JH (2023) Renal elasticity and perfusion changes on ultrasonography in an early-stage diabetic rat model. Quant Imaging Med Surg 13:7667\u20137679. https:\/\/doi.org\/10.21037\/qims-23-409","journal-title":"Quant Imaging Med Surg"},{"key":"845_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01914-1","volume":"22","author":"X Li","year":"2024","unstructured":"Li X, Li Q, Jiang X, Song S, Zou W, Yang Q, Liu S, Chen S, Wang C (2024) Inhibition of SGLT2 protects podocytes in diabetic kidney disease by rebalancing mitochondria-associated endoplasmic reticulum membranes. Cell Commun Signal 22:534. https:\/\/doi.org\/10.1186\/s12964-024-01914-1","journal-title":"Cell Commun Signal"},{"key":"845_CR85","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1007\/s10753-025-02258-9","volume":"48","author":"S Li","year":"2025","unstructured":"Li S, Wang J, Chen Y, Cheng Y, Wang Y, Xu N, Wang H, Wang L, Chi Y, Ye X, Shi Y, Fang J, Yao X, Huang J, Xia Q, Bai T, Zhu B (2025) Canagliflozin attenuates podocyte inflammatory injury through suppressing the TXNIP\/NLRP3 signaling pathway in diabetic kidney disease mice. Inflammation 48:3180\u20133193. https:\/\/doi.org\/10.1007\/s10753-025-02258-9","journal-title":"Inflammation"},{"key":"845_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154334","volume":"111","author":"X Liu","year":"2020","unstructured":"Liu X, Xu C, Xu L, Li X, Sun H, Xue M, Li T, Yu X, Sun B, Chen L (2020) Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK\/SP1\/PGAM5 pathway. Metabolism 111:154334. https:\/\/doi.org\/10.1016\/j.metabol.2020.154334","journal-title":"Metabolism"},{"key":"845_CR87","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/path.5862","volume":"256","author":"M Locatelli","year":"2022","unstructured":"Locatelli M, Zoja C, Conti S, Cerullo D, Corna D, Rottoli D, Zanchi C, Tomasoni S, Remuzzi G, Benigni A (2022) Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A\/caveolin-1\/PV-1 signaling pathway. J Pathol 256:468\u2013479. https:\/\/doi.org\/10.1002\/path.5862","journal-title":"J Pathol"},{"key":"845_CR88","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7150\/ijbs.33007","volume":"16","author":"YH Lu","year":"2020","unstructured":"Lu YH, Chang YP, Li T, Han F, Li CJ, Li XY, Xue M, Cheng Y, Meng ZY, Han Z, Sun B, Chen LM (2020) Empagliflozin attenuates hyperuricemia by upregulation of ABCG2 via AMPK\/AKT\/CREB signaling pathway in type 2 diabetic mice. Int J Biol Sci 16:529\u2013542. https:\/\/doi.org\/10.7150\/ijbs.33007","journal-title":"Int J Biol Sci"},{"key":"845_CR89","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12967-022-03629-8","volume":"20","author":"YP Lu","year":"2022","unstructured":"Lu YP, Zhang ZY, Wu HW, Fang LJ, Hu B, Tang C, Zhang YQ, Yin L, Tang DE, Zheng ZH, Zhu T, Dai Y (2022) SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease. J Transl Med 20:420. https:\/\/doi.org\/10.1186\/s12967-022-03629-8","journal-title":"J Transl Med"},{"key":"845_CR90","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.freeradbiomed.2022.12.088","volume":"195","author":"Q Lu","year":"2023","unstructured":"Lu Q, Yang L, Xiao JJ, Liu Q, Ni L, Hu JW, Yu H, Wu X, Zhang BF (2023) Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK\/NRF2 pathway. Free Radic Biol Med 195:89\u2013102. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2022.12.088","journal-title":"Free Radic Biol Med"},{"key":"845_CR91","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1021\/acsptsci.4c00552","volume":"8","author":"PAB Machado-Junior","year":"2025","unstructured":"Machado-Junior PAB, Lass A, de Bortolo J, Anizelli LB, Rocha MT, Proen\u00e7a HMS, Carvalhal SRS, Mehanna SH, Nagashima S, Fernandes LC, de Noronha L, de Moraes TP, Pinho RA (2025) Sodium-glucose Cotransporter-2 inhibitor improves renal injury by regulating the redox profile, inflammatory parameters, and Pyroptosis in an experimental model of diabetic kidney disease. ACS Pharmacol Transl Sci 8:1270\u20131281. https:\/\/doi.org\/10.1021\/acsptsci.4c00552","journal-title":"ACS Pharmacol Transl Sci"},{"key":"845_CR92","doi-asserted-by":"publisher","first-page":"530","DOI":"10.25122\/jml-2023-0301","volume":"17","author":"Z Madhag","year":"2024","unstructured":"Madhag Z, Al-Isawi Z (2024) Empagliflozin alone and in combination with metformin mitigates diabetes-associated renal complications. J Med Life 17:530\u2013535. https:\/\/doi.org\/10.25122\/jml-2023-0301","journal-title":"J Med Life"},{"key":"845_CR93","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.1038\/s41598-019-41253-7","volume":"9","author":"T Maki","year":"2019","unstructured":"Maki T, Maeno S, Maeda Y, Yamato M, Sonoda N, Ogawa Y, Wakisaka M, Inoguchi T (2019) Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: a possible role of SGLT2 in mesangial cells. Sci Rep 9:4703. https:\/\/doi.org\/10.1038\/s41598-019-41253-7","journal-title":"Sci Rep"},{"key":"845_CR94","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1055\/a-0815-4908","volume":"128","author":"N Manne","year":"2020","unstructured":"Manne N, Ginjupalli GK, Rice KM, Arvapalli R, Graffeo VA, Bandarupalli VVK, Blough ER (2020) Long-term treatment with empagliflozin attenuates renal damage in obese Zucker rat. Exp Clin Endocrinol Diabetes 128:512\u2013519. https:\/\/doi.org\/10.1055\/a-0815-4908","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"845_CR95","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/15548627.2024.2410621","volume":"21","author":"S Matsui","year":"2025","unstructured":"Matsui S, Yamamoto T, Takabatake Y, Takahashi A, Namba-Hamano T, Matsuda J, Minami S, Sakai S, Yonishi H, Nakamura J, Maeda S, Matsumoto A, Matsui I, Yanagita M, Isaka Y (2025a) Empagliflozin protects the kidney by reducing toxic ALB (albumin) exposure and preventing autophagic stagnation in proximal tubules. Autophagy 21:583\u2013597. https:\/\/doi.org\/10.1080\/15548627.2024.2410621","journal-title":"Autophagy"},{"key":"845_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-025-01138-0","volume":"31","author":"T Matsui","year":"2025","unstructured":"Matsui T, Sotokawauchi A, Nishino Y, Koga Y, Yamagishi SI (2025b) Empagliflozin ameliorates renal and metabolic derangements in obese type 2 diabetic mice by blocking advanced glycation end product-receptor axis. Mol Med 31:88. https:\/\/doi.org\/10.1186\/s10020-025-01138-0","journal-title":"Mol Med"},{"key":"845_CR97","doi-asserted-by":"publisher","unstructured":"Matthews JR, Schlaich MP, Rakoczy EP, Matthews VB, Herat LY (2022) The effect of SGLT2 inhibition on diabetic kidney disease in a model of diabetic retinopathy. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10030522","DOI":"10.3390\/biomedicines10030522"},{"issue":"Suppl 3","key":"845_CR98","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1124\/jpet.003.933440","volume":"389","author":"M Michel","year":"2024","unstructured":"Michel M, Ashfaq A, Meineck M, Weinmann-Menke J, Arioglu Inan E, Pautz A (2024) No evidence for beneficial empagliflozin effects in the kidney of female rats in a streptozotocin-induced model of type 1 diabetes. J Pharmacol Exp Ther 389(Suppl 3):3","journal-title":"J Pharmacol Exp Ther"},{"key":"845_CR99","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae396","volume":"18","author":"R Minutolo","year":"2025","unstructured":"Minutolo R, Borrelli S, Ambrosini A, Amoroso L, Aucella F, Batini V, Battaglia Y, Bregoli L, Cantaluppi V, Cianciolo G, Conti P, Fabbrini P, Giammarresi C, Imbalzano E, La Rosa S, Marengo M, Montinaro V, Musone D, Napoli M, Nappi F, Pluvio C, Santoro D, Scarpioni R, Sopranzi F, Tullio T, De Nicola L (2025) Efficacy and safety of dapagliflozin in patients with CKD: real-world experience in 93 Italian renal clinics. Clin Kidney J 18:sfae396. https:\/\/doi.org\/10.1093\/ckj\/sfae396","journal-title":"Clin Kidney J"},{"key":"845_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108107","volume":"162","author":"KN Miyata","year":"2020","unstructured":"Miyata KN, Zhao S, Wu CH, Lo CS, Ghosh A, Chenier I, Filep JG, Ingelfinger JR, Zhang SL, Chan JSD (2020) Comparison of the effects of insulin and SGLT2 inhibitor on the renal renin-angiotensin system in type 1 diabetes mice. Diabetes Res Clin Pract 162:108107. https:\/\/doi.org\/10.1016\/j.diabres.2020.108107","journal-title":"Diabetes Res Clin Pract"},{"key":"845_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.178024","volume":"1005","author":"MC Moraes","year":"2025","unstructured":"Moraes MC, Oliveira LBF, Campos MR, Barahuna-Filho PFR, Cardozo PL, Vieira MAR, Ribeiro FM, Vieira LB, Peruchetti DB (2025) Kidney dysfunction induced by a hyperpalatable diet: role of sodium\/glucose Co-transporter inhibition in male mice. Eur J Pharmacol 1005:178024. https:\/\/doi.org\/10.1016\/j.ejphar.2025.178024","journal-title":"Eur J Pharmacol"},{"key":"845_CR102","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1681\/asn.2019070703","volume":"31","author":"M Motrapu","year":"2020","unstructured":"Motrapu M, \u015awiderska MK, Mesas I, Marschner JA, Lei Y, Martinez Valenzuela L, Fu J, Lee K, Angelotti ML, Antonelli G, Romagnani P, Anders HJ, Anguiano L (2020) Drug testing for residual progression of diabetic kidney disease in mice beyond therapy with metformin, ramipril, and empagliflozin. J Am Soc Nephrol 31:1729\u20131745. https:\/\/doi.org\/10.1681\/asn.2019070703","journal-title":"J Am Soc Nephrol"},{"key":"845_CR103","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/bph.12269","volume":"170","author":"T Nagata","year":"2013","unstructured":"Nagata T, Fukuzawa T, Takeda M, Fukuzawa M, Mori T, Nihei T, Honda K, Suzuki Y, Kawabe Y (2013) Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db\/db mice. Br J Pharmacol 170:519\u2013531. https:\/\/doi.org\/10.1111\/bph.12269","journal-title":"Br J Pharmacol"},{"key":"845_CR104","volume-title":"Type 2 diabetes in adults: management","author":"National Institute for Health and Care Excellence","year":"2019","unstructured":"National Institute for Health and Care Excellence (2019) Type 2 diabetes in adults: management. National Institute for Health and Care Excellence, London"},{"key":"845_CR105","doi-asserted-by":"publisher","first-page":"C452","DOI":"10.1152\/ajpcell.00651.2024","volume":"328","author":"Y Ni","year":"2025","unstructured":"Ni Y, Du H, Ke L, Zheng L, Nan S, Ni L, Pan Y, Fu Z, He Q, Jin J (2025) Gut-kidney interaction reinforces dapagliflozin-mediated alleviation in diabetic nephropathy. Am J Physiol Cell Physiol 328:C452\u2013C466. https:\/\/doi.org\/10.1152\/ajpcell.00651.2024","journal-title":"Am J Physiol Cell Physiol"},{"key":"845_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172537","volume":"860","author":"SA N\u00f8rgaard","year":"2019","unstructured":"N\u00f8rgaard SA, Briand F, Sand FW, Galsgaard ED, S\u00f8ndergaard H, S\u00f8rensen DB, Sulpice T (2019) Nephropathy in diabetic db\/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin. Eur J Pharmacol 860:172537. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172537","journal-title":"Eur J Pharmacol"},{"key":"845_CR107","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/s0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group, consortium Sim-ac-r-t","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies Group, consortium Sim-ac-r-t (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400:1788\u20131801. https:\/\/doi.org\/10.1016\/s0140-6736(22)02074-8","journal-title":"Lancet"},{"key":"845_CR108","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1007\/s00125-021-05399-2","volume":"64","author":"ML O\u2019Donoghue","year":"2021","unstructured":"O\u2019Donoghue ML, Kato ET, Mosenzon O, Murphy SA, Cahn A, Herrera M, Tankova T, \u0160mahelov\u00e1 A, Merlini P, Gause-Nilsson I, Langkilde AM, McGuire DK, Wilding JPH, Leiter LA, Bhatt DL, Raz I, Sabatine MS, Wiviott SD (2021) The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. Diabetologia 64:1226\u20131234. https:\/\/doi.org\/10.1007\/s00125-021-05399-2","journal-title":"Diabetologia"},{"key":"845_CR109","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1055\/s-0034-1395609","volume":"47","author":"A Ojima","year":"2015","unstructured":"Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S (2015) Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm Metab Res 47:686\u2013692. https:\/\/doi.org\/10.1055\/s-0034-1395609","journal-title":"Horm Metab Res"},{"key":"845_CR110","doi-asserted-by":"publisher","unstructured":"Okuma H, Mori K, Nakamura S, Sekine T, Ogawa Y, Tsuchiya K (2021) Ipragliflozin ameliorates diabetic nephropathy associated with perirenal adipose expansion in mice. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22147329","DOI":"10.3390\/ijms22147329"},{"key":"845_CR111","doi-asserted-by":"publisher","first-page":"F712","DOI":"10.1152\/ajprenal.00264.2020","volume":"319","author":"A Onishi","year":"2020","unstructured":"Onishi A, Fu Y, Patel R, Darshi M, Crespo-Masip M, Huang W, Song P, Freeman B, Kim YC, Soleimani M, Sharma K, Thomson SC, Vallon V (2020) A role for tubular Na+\/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin. Am J Physiol Renal Physiol 319:F712\u2013F728. https:\/\/doi.org\/10.1152\/ajprenal.00264.2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"845_CR112","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.biopha.2018.10.100","volume":"109","author":"MA Oraby","year":"2019","unstructured":"Oraby MA, El-Yamany MF, Safar MM, Assaf N, Ghoneim HA (2019) Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats. Biomed Pharmacother 109:910\u2013920. https:\/\/doi.org\/10.1016\/j.biopha.2018.10.100","journal-title":"Biomed Pharmacother"},{"key":"845_CR113","doi-asserted-by":"publisher","first-page":"F149","DOI":"10.1152\/ajprenal.00154.2021","volume":"321","author":"MV \u00d8stergaard","year":"2021","unstructured":"\u00d8stergaard MV, Secher T, Christensen M, Salinas CG, Roostalu U, Skytte JL, Rune I, Hansen HH, Jelsing J, Vrang N, Fink LN (2021) Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease. Am J Physiol Renal Physiol 321:F149\u2013f161. https:\/\/doi.org\/10.1152\/ajprenal.00154.2021","journal-title":"Am J Physiol Renal Physiol"},{"key":"845_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154405","volume":"113","author":"H Otomo","year":"2020","unstructured":"Otomo H, Nara M, Kato S, Shimizu T, Suganuma Y, Sato T, Morii T, Yamada Y, Fujita H (2020) Sodium-glucose cotransporter 2 inhibition attenuates protein overload in renal proximal tubule via suppression of megalin O-GlcNacylation in progressive diabetic nephropathy. Metabolism 113:154405. https:\/\/doi.org\/10.1016\/j.metabol.2020.154405","journal-title":"Metabolism"},{"key":"845_CR115","doi-asserted-by":"publisher","unstructured":"P\u00e9rez-Villavicencio R, Flores-Estrada J, Franco M, Escalante B, P\u00e9rez-M\u00e9ndez O, Mercado A, Bautista-P\u00e9rez R (2022) Effect of empagliflozin on sphingolipid catabolism in diabetic and hypertensive rats. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23052883","DOI":"10.3390\/ijms23052883"},{"key":"845_CR116","first-page":"129","volume":"40","author":"Y Qian","year":"2024","unstructured":"Qian Y, Wan L, Lu Y, Ni W, Yang H, Pan Y, Chen W (2024) Empagliflozin inhibits inflammatory response and alleviates renal injury in type 2 diabetic rats by up-regulating the expression of exchange protein 1 directly activated by cAMP (Epac1). Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 40:129\u2013134","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"845_CR117","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8337823","volume":"2022","author":"R Saad","year":"2022","unstructured":"Saad R, Tadmor H, Ertracht O, Nakhoul N, Nakhoul F, Evgeny F, Atar S (2022) The molecular effects of SGLT2i empagliflozin on the autophagy pathway in diabetes mellitus type 2 and its complications. J Diabetes Res 2022:8337823. https:\/\/doi.org\/10.1155\/2022\/8337823","journal-title":"J Diabetes Res"},{"key":"845_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1706838","volume":"16","author":"M Sakamoto","year":"2025","unstructured":"Sakamoto M, Hasuzawa N, Wang L, Tashiro K, Kitamura M, Iwata S, Wada N, Nomura S, Moriyama S, Gobaru M, Inoguchi Y, Nagayama A, Ashida K, Moriyama Y, Nomura M (2025) Sodium-glucose cotransporter 2 inhibitors-but not insulin-enhance renal branched-chain amino acid catabolism. Front Endocrinol (Lausanne) 16:1706838. https:\/\/doi.org\/10.3389\/fendo.2025.1706838","journal-title":"Front Endocrinol (Lausanne)"},{"key":"845_CR119","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3803\/EnM.2025.2339","volume":"41","author":"H Sakuma","year":"2026","unstructured":"Sakuma H, Murakoshi M, Hagiwara S, Shibata T, Suzuki Y, Gohda T (2026) Effects of progranulin deficiency on inflammation and fibrosis in the kidneys and liver of diabetic mice fed a high-fat diet. Endocrinol Metab (Seoul) 41:138\u2013151. https:\/\/doi.org\/10.3803\/EnM.2025.2339","journal-title":"Endocrinol Metab (Seoul)"},{"key":"845_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115629","volume":"167","author":"E Samaan","year":"2023","unstructured":"Samaan E, Ramadan NM, Abdulaziz HMM, Ibrahim D, El-Sherbiny M, ElBayar R, Ghattas Y, Abdlmalek J, Bayali O, Elhusseini Y, Maghrabia A, El-Gamal R (2023) DPP-4i versus SGLT2i as modulators of PHD3\/HIF-2\u03b1 pathway in the diabetic kidney. Biomed Pharmacother 167:115629. https:\/\/doi.org\/10.1016\/j.biopha.2023.115629","journal-title":"Biomed Pharmacother"},{"key":"845_CR121","doi-asserted-by":"publisher","first-page":"45","DOI":"10.33549\/physiolres.934533","volume":"70","author":"R Sano","year":"2021","unstructured":"Sano R, Ishii Y, Yamanaka M, Yasui Y, Kemmochi Y, Kuroki F, Sugimoto M, Fukuda S, Sasase T, Miyajima K, Nakae D, Ohta T (2021) Glomerular hyperfiltration with hyperglycemia in the spontaneously diabetic Torii (SDT) fatty rat, an obese type 2 diabetic model. Physiol Res 70:45\u201354. https:\/\/doi.org\/10.33549\/physiolres.934533","journal-title":"Physiol Res"},{"key":"845_CR122","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s00125-023-06078-0","volume":"67","author":"M Shao","year":"2024","unstructured":"Shao M, Chen D, Wang Q, Guo F, Wei F, Zhang W, Gan T, Luo Y, Fan X, Du P, Liu Y, Ma X, Ren G, Song Y, Zhao Y, Qin G (2024) Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns. Diabetologia 67:738\u2013754. https:\/\/doi.org\/10.1007\/s00125-023-06078-0","journal-title":"Diabetologia"},{"key":"845_CR123","doi-asserted-by":"publisher","first-page":"E362","DOI":"10.1152\/ajpendo.00254.2024","volume":"328","author":"N Sharma","year":"2025","unstructured":"Sharma N, Liu W, Tsai XE, Wang Z, Outtrim C, Tang A, Pieper MP, Reinhart GA, Huang Y (2025) A novel soluble guanylate cyclase activator, avenciguat, in combination with empagliflozin, protects against renal and hepatic injury in diabetic db\/db mice. Am J Physiol Endocrinol Metab 328:E362\u2013E376. https:\/\/doi.org\/10.1152\/ajpendo.00254.2024","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"845_CR124","doi-asserted-by":"publisher","first-page":"5391","DOI":"10.1039\/d3fo01379k","volume":"14","author":"V Shelke","year":"2023","unstructured":"Shelke V, Kale A, Dagar N, Habshi T, Gaikwad AB (2023) Concomitant inhibition of TLR-4 and SGLT2 by phloretin and empagliflozin prevents diabetes-associated ischemic acute kidney injury. Food Funct 14:5391\u20135403. https:\/\/doi.org\/10.1039\/d3fo01379k","journal-title":"Food Funct"},{"key":"845_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1620230","volume":"16","author":"X Shi","year":"2025","unstructured":"Shi X, Zou W, Li X, Liu S, Hu T, Li Q, Zhang T, Chen L, Wu S, Wang C, Jin Y (2025) SGLT2 inhibition attenuates diabetic tubulopathy by suppressing SGK1-mediated pyroptosis. Front Endocrinol (Lausanne) 16:1620230. https:\/\/doi.org\/10.3389\/fendo.2025.1620230","journal-title":"Front Endocrinol (Lausanne)"},{"key":"845_CR126","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s11010-025-05437-2","volume":"481","author":"S Shi","year":"2026","unstructured":"Shi S, Li W, Yang L, Zhang J, Wu X (2026) Empagliflozin alleviates lipid deposition and inflammation in diabetic kidney disease by downregulating C1QC. Mol Cell Biochem 481:885\u2013898. https:\/\/doi.org\/10.1007\/s11010-025-05437-2","journal-title":"Mol Cell Biochem"},{"key":"845_CR127","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46402-6","volume":"9","author":"R Shibusawa","year":"2019","unstructured":"Shibusawa R, Yamada E, Okada S, Nakajima Y, Bastie CC, Maeshima A, Kaira K, Yamada M (2019) Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death. Sci Rep 9:9887. https:\/\/doi.org\/10.1038\/s41598-019-46402-6","journal-title":"Sci Rep"},{"key":"845_CR128","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165703","volume":"11","author":"SJ Shin","year":"2016","unstructured":"Shin SJ, Chung S, Kim SJ, Lee EM, Yoo YH, Kim JW, Ahn YB, Kim ES, Moon SD, Kim MJ, Ko SH (2016) Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS One 11:e0165703. https:\/\/doi.org\/10.1371\/journal.pone.0165703","journal-title":"PLoS One"},{"key":"845_CR129","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1139\/cjpp-2022-0082","volume":"100","author":"D Stuart","year":"2022","unstructured":"Stuart D, Peterson CS, Hu C, Revelo MP, Huang Y, Kohan DE, Ramkumar N (2022) Lack of renoprotective effects of targeting the endothelin A receptor and (or) sodium glucose transporter 2 in a mouse model of Type 2 diabetic kidney disease. Can J Physiol Pharmacol 100:763\u2013771. https:\/\/doi.org\/10.1139\/cjpp-2022-0082","journal-title":"Can J Physiol Pharmacol"},{"key":"845_CR130","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13098-022-00886-x","volume":"14","author":"H Sun","year":"2022","unstructured":"Sun H, Chen J, Hua Y, Zhang Y, Liu Z (2022) New insights into the role of empagliflozin on diabetic renal tubular lipid accumulation. Diabetol Metab Syndr 14:121. https:\/\/doi.org\/10.1186\/s13098-022-00886-x","journal-title":"Diabetol Metab Syndr"},{"key":"845_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174076","volume":"901","author":"A Tahara","year":"2021","unstructured":"Tahara A (2021) Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH. Eur J Pharmacol 901:174076. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174076","journal-title":"Eur J Pharmacol"},{"key":"845_CR132","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00210-018-1469-5","volume":"391","author":"A Tahara","year":"2018","unstructured":"Tahara A, Takasu T (2018a) Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice. Naunyn Schmiedeberg\u2019s Arch Pharmacol 391:395\u2013406. https:\/\/doi.org\/10.1007\/s00210-018-1469-5","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"845_CR133","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejphar.2018.04.024","volume":"830","author":"A Tahara","year":"2018","unstructured":"Tahara A, Takasu T (2018b) Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice. Eur J Pharmacol 830:68\u201375. https:\/\/doi.org\/10.1016\/j.ejphar.2018.04.024","journal-title":"Eur J Pharmacol"},{"key":"845_CR134","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/jdi.12802","volume":"9","author":"S Takagi","year":"2018","unstructured":"Takagi S, Li J, Takagaki Y, Kitada M, Nitta K, Takasu T, Kanasaki K, Koya D (2018) Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. J Diabetes Investig 9:1025\u20131032. https:\/\/doi.org\/10.1111\/jdi.12802","journal-title":"J Diabetes Investig"},{"key":"845_CR135","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1248\/bpb.b19-00351","volume":"42","author":"S Takakura","year":"2019","unstructured":"Takakura S, Takasu T (2019) Acute and direct effects of sodium-glucose cotransporter 2 inhibition on glomerular filtration rate in spontaneously diabetic Torii fatty rats. Biol Pharm Bull 42:1707\u20131712. https:\/\/doi.org\/10.1248\/bpb.b19-00351","journal-title":"Biol Pharm Bull"},{"key":"845_CR136","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ebiom.2018.09.048","volume":"36","author":"Y Takiyama","year":"2018","unstructured":"Takiyama Y, Sera T, Nakamura M, Ishizeki K, Saijo Y, Yanagimachi T, Maeda M, Bessho R, Takiyama T, Kitsunai H, Sakagami H, Fujishiro D, Fujita Y, Makino Y, Abiko A, Hoshino M, Uesugi K, Yagi N, Ota T, Haneda M (2018) Impacts of diabetes and an SGLT2 inhibitor on the glomerular number and volume in db\/db mice, as estimated by synchrotron radiation micro-CT at SPring-8. EBioMedicine 36:329\u2013346. https:\/\/doi.org\/10.1016\/j.ebiom.2018.09.048","journal-title":"EBioMedicine"},{"key":"845_CR137","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.kint.2018.04.025","volume":"94","author":"S Tanaka","year":"2018","unstructured":"Tanaka S, Sugiura Y, Saito H, Sugahara M, Higashijima Y, Yamaguchi J, Inagi R, Suematsu M, Nangaku M, Tanaka T (2018) Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice. Kidney Int 94:912\u2013925. https:\/\/doi.org\/10.1016\/j.kint.2018.04.025","journal-title":"Kidney Int"},{"key":"845_CR138","doi-asserted-by":"publisher","first-page":"E563","DOI":"10.1152\/ajpendo.00086.2017","volume":"313","author":"L Tang","year":"2017","unstructured":"Tang L, Wu Y, Tian M, Sj\u00f6str\u00f6m CD, Johansson U, Peng XR, Smith DM, Huang Y (2017) Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am J Physiol Endocrinol Metab 313:E563\u2013e576. https:\/\/doi.org\/10.1152\/ajpendo.00086.2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"845_CR139","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100777","volume":"9","author":"N Terami","year":"2014","unstructured":"Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A, Eguchi J, Horiguchi CS, Nishii N, Yamada H, Takei K, Makino H (2014) Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice. PLoS One 9:e100777. https:\/\/doi.org\/10.1371\/journal.pone.0100777","journal-title":"PLoS One"},{"key":"845_CR140","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","volume":"302","author":"SC Thomson","year":"2012","unstructured":"Thomson SC, Rieg T, Miracle C, Mansoury H, Whaley J, Vallon V, Singh P (2012) Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 302:R75\u2013R83. https:\/\/doi.org\/10.1152\/ajpregu.00357.2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"845_CR141","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22978","volume":"36","author":"L Thongnak","year":"2022","unstructured":"Thongnak L, Pengrattanachot N, Promsan S, Phengpol N, Sutthasupha P, Chatsudthipong V, Lungkaphin A (2022) The combination of dapagliflozin and statins ameliorates renal injury through attenuating the activation of inflammasome-mediated autophagy in insulin-resistant rats. J Biochem Mol Toxicol 36:e22978. https:\/\/doi.org\/10.1002\/jbt.22978","journal-title":"J Biochem Mol Toxicol"},{"key":"845_CR142","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/s1875-5364(16)30061-9","volume":"14","author":"CM Tian","year":"2016","unstructured":"Tian CM, Jiang X, Ouyang XX, Zhang YO, Xie WD (2016) Berberine enhances antidiabetic effects and attenuates untoward effects of canagliflozin in streptozotocin-induced diabetic mice. Chin J Nat Med 14:518\u2013526. https:\/\/doi.org\/10.1016\/s1875-5364(16)30061-9","journal-title":"Chin J Nat Med"},{"key":"845_CR143","doi-asserted-by":"publisher","DOI":"10.1080\/0886022x.2024.2438857","volume":"47","author":"Y Tian","year":"2025","unstructured":"Tian Y, Zhou C, Yan Q, Li Z, Chen D, Feng B, Song J (2025) Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through \u03b2-hydroxybutyrate production. Ren Fail 47:2438857. https:\/\/doi.org\/10.1080\/0886022x.2024.2438857","journal-title":"Ren Fail"},{"key":"845_CR144","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cmet.2020.06.020","volume":"32","author":"I Tomita","year":"2020","unstructured":"Tomita I, Kume S, Sugahara S, Osawa N, Yamahara K, Yasuda-Yamahara M, Takeda N, Chin-Kanasaki M, Kaneko T, Mayoux E, Mark M, Yanagita M, Ogita H, Araki SI, Maegawa H (2020) SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab 32:404\u2013419.e406. https:\/\/doi.org\/10.1016\/j.cmet.2020.06.020","journal-title":"Cell Metab"},{"key":"845_CR145","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0295284","volume":"18","author":"M Trentin-Sonoda","year":"2023","unstructured":"Trentin-Sonoda M, Cheff V, Gutsol A, H\u00e9bert RL (2023) Sex-dependent effects of canagliflozin on kidney protection in mice with combined hypertension-type 1 diabetes. PLoS One 18:e0295284. https:\/\/doi.org\/10.1371\/journal.pone.0295284","journal-title":"PLoS One"},{"key":"845_CR146","doi-asserted-by":"publisher","unstructured":"Trentin-Sonoda M, Burelle Y, Gutsol A, Myette RL, H\u00e9bert RL (2025) Canagliflozin promotes structural and functional changes in proximal tubular cell mitochondria of hypertensive-diabetic mice. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms262411988","DOI":"10.3390\/ijms262411988"},{"key":"845_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e10615","volume":"8","author":"N Uehara-Watanabe","year":"2022","unstructured":"Uehara-Watanabe N, Okuno-Ozeki N, Nakamura I, Nakata T, Nakai K, Yagi-Tomita A, Ida T, Yamashita N, Kamezaki M, Kirita Y, Matoba S, Tamagaki K, Kusaba T (2022) Proximal tubular epithelia-specific transcriptomics of diabetic mice treated with dapagliflozin. Heliyon 8:e10615. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e10615","journal-title":"Heliyon"},{"key":"845_CR148","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.1038\/s41598-018-25054-y","volume":"8","author":"H Umino","year":"2018","unstructured":"Umino H, Hasegawa K, Minakuchi H, Muraoka H, Kawaguchi T, Kanda T, Tokuyama H, Wakino S, Itoh H (2018) High basolateral glucose increases sodium-glucose cotransporter 2 and reduces sirtuin-1 in renal tubules through glucose transporter-2 detection. Sci Rep 8:6791. https:\/\/doi.org\/10.1038\/s41598-018-25054-y","journal-title":"Sci Rep"},{"key":"845_CR149","doi-asserted-by":"publisher","first-page":"F156","DOI":"10.1152\/ajprenal.00409.2012","volume":"304","author":"V Vallon","year":"2013","unstructured":"Vallon V, Rose M, Gerasimova M, Satriano J, Platt KA, Koepsell H, Cunard R, Sharma K, Thomson SC, Rieg T (2013) Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hpyerfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol 304:F156\u2013F167. https:\/\/doi.org\/10.1152\/ajprenal.00409.2012","journal-title":"Am J Physiol"},{"key":"845_CR150","doi-asserted-by":"publisher","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","volume":"306","author":"V Vallon","year":"2014","unstructured":"Vallon V, Gerasimova M, Rose M, Masuda T, Satriano J, Mayoux E, Koepsell H, Thompson SC, Rieg T (2014) SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycermia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol 306:F194\u2013F204. https:\/\/doi.org\/10.1152\/ajprenal.00520.2013","journal-title":"Am J Physiol"},{"key":"845_CR151","doi-asserted-by":"publisher","unstructured":"Vergara A, Jacobs-Cacha C, Llorens-Cebria C, Ortiz A, Martinez-Diaz I, Martos N, Dominguez-B\u00e1ez P, Van den Bosch MM, Bermejo S, Pieper MP, Benito B, Soler MJ (2022) Enhanced cardiorenal protective effects of combining SGLT2 inhibition, endothelin receptor antagonism and RAS blockade in type 2 diabetic mice. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232112823","DOI":"10.3390\/ijms232112823"},{"key":"845_CR152","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.kint.2024.05.006","volume":"106","author":"Y Wada","year":"2024","unstructured":"Wada Y, Kidokoro K, Kondo M, Tokuyama A, Kadoya H, Nagasu H, Kanda E, Sasaki T, Cherney DZI, Kashihara N (2024) Evaluation of glomerular hemodynamic changes by sodium-glucose-transporter 2 inhibition in type 2 diabetic rats using in vivo imaging. Kidney Int 106:408\u2013418. https:\/\/doi.org\/10.1016\/j.kint.2024.05.006","journal-title":"Kidney Int"},{"key":"845_CR153","doi-asserted-by":"publisher","unstructured":"Wang D, Luo Y, Wang X, Orlicky DJ, Myakala K, Yang P, Levi M (2018) The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents renal and liver disease in Western diet induced obesity mice. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19010137","DOI":"10.3390\/ijms19010137"},{"key":"845_CR154","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/2211-5463.13147","volume":"11","author":"D Wang","year":"2021","unstructured":"Wang D, Zhang Z, Si Z, Yang Y, Li S, Xue Y (2021) Dapagliflozin reverses the imbalance of T helper 17 and T regulatory cells by inhibiting SGK1 in a mouse model of diabetic kidney disease. FEBS Open Bio 11:1395\u20131405. https:\/\/doi.org\/10.1002\/2211-5463.13147","journal-title":"FEBS Open Bio"},{"key":"845_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.118572","volume":"334","author":"Y Wang","year":"2024","unstructured":"Wang Y, Yu L, Li Y, Cha S, Shi L, Wang J, Ge F, Huang C, Huang H, Tu Y, Wan Y, Shen S (2024a) Supplemented Gegen Qinlian Decoction Formula attenuates podocyte mitochondrial fission and renal fibrosis in diabetic kidney disease by inhibiting TNF-\u03b1-mediated necroptosis, compared with empagliflozin. J Ethnopharmacol 334:118572. https:\/\/doi.org\/10.1016\/j.jep.2024.118572","journal-title":"J Ethnopharmacol"},{"key":"845_CR156","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1089\/ars.2022.0169","volume":"40","author":"YH Wang","year":"2024","unstructured":"Wang YH, Chang DY, Zhao MH, Chen M (2024b) Dapagliflozin alleviates diabetic kidney disease via hypoxia inducible factor 1\u03b1\/heme oxygenase 1-mediated ferroptosis. Antioxid Redox Signal 40:492\u2013509. https:\/\/doi.org\/10.1089\/ars.2022.0169","journal-title":"Antioxid Redox Signal"},{"key":"845_CR157","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1007\/s40618-025-02650-0","volume":"48","author":"S Wang","year":"2025","unstructured":"Wang S, Zhang X, Chong N, Chen D, Shu J, Wang R, Wang Q, Xu Y (2025) Dapagliflozin ameliorates high glucose-induced epithelial-mesenchymal transition via up-regulating ACE2 mediated by EZH2 in diabetic nephropathy. J Endocrinol Investig 48:2499\u20132509. https:\/\/doi.org\/10.1007\/s40618-025-02650-0","journal-title":"J Endocrinol Investig"},{"key":"845_CR158","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s11357-022-00610-7","volume":"44","author":"JM Williams","year":"2022","unstructured":"Williams JM, Murphy SR, Wu W, Border JJ, Fan F, Roman RJ (2022) Renoprotective effects of empagliflozin in type 1 and type 2 models of diabetic nephropathy superimposed with hypertension. Geroscience 44:2845\u20132861. https:\/\/doi.org\/10.1007\/s11357-022-00610-7","journal-title":"Geroscience"},{"key":"845_CR159","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"845_CR160","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1159\/000499597","volume":"49","author":"TC Woods","year":"2019","unstructured":"Woods TC, Satou R, Miyata K, Katsurada A, Dugas CM, Klingenberg NC, Fonseca VA, Navar LG (2019) Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus. Am J Nephrol 49:331\u2013342. https:\/\/doi.org\/10.1159\/000499597","journal-title":"Am J Nephrol"},{"key":"845_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112267","volume":"144","author":"X Wu","year":"2021","unstructured":"Wu X, Li H, Wan Z, Wang R, Liu J, Liu Q, Zhao H, Wang Z, Zhang H, Guo H, Qi C, Jiao X, Li X (2021) The combination of ursolic acid and empagliflozin relieves diabetic nephropathy by reducing inflammation, oxidative stress and renal fibrosis. Biomed Pharmacother 144:112267. https:\/\/doi.org\/10.1016\/j.biopha.2021.112267","journal-title":"Biomed Pharmacother"},{"key":"845_CR162","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1026040","volume":"14","author":"J Wu","year":"2023","unstructured":"Wu J, Chen Y, Yang H, Gu L, Ni Z, Mou S, Shen J, Che X (2023) Sodium glucose co-transporter 2 (SGLT2) inhibition via dapagliflozin improves diabetic kidney disease (DKD) over time associatied with increasing effect on the gut microbiota in db\/db mice. Front Endocrinol (Lausanne) 14:1026040. https:\/\/doi.org\/10.3389\/fendo.2023.1026040","journal-title":"Front Endocrinol (Lausanne)"},{"key":"845_CR163","doi-asserted-by":"publisher","first-page":"565","DOI":"10.12047\/j.cjap.6001.2020.119","volume":"36","author":"Y Xu","year":"2020","unstructured":"Xu Y, Chen XH, Bai LW, Yin QF, Feng CY, Zhang QG (2020). Effect of dapagliflozin on gene expression of glucose transporter 2 and glucose transporter 4 in kidney of type 2 diabetic rats) Zhongguo Ying Yong Sheng Li Xue Za Zhi 36:565\u2013570. https:\/\/doi.org\/10.12047\/j.cjap.6001.2020.119","journal-title":"Zhongguo Ying Yong Sheng Li Xue Za Zhi"},{"key":"845_CR164","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3892\/etm.2023.12271","volume":"26","author":"S Xue","year":"2023","unstructured":"Xue S, Li YX, Lu XX, Tang W (2023) Dapagliflozin can alleviate renal fibrosis in rats with streptozotocin-induced type 2 diabetes mellitus. Exp Ther Med 26:572. https:\/\/doi.org\/10.3892\/etm.2023.12271","journal-title":"Exp Ther Med"},{"key":"845_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109272","volume":"113","author":"H Yang","year":"2022","unstructured":"Yang H, Mei Z, Chen W, Pan Y, Liu L, Zhao R, Ni W, Wang Y, Fei C (2022) Therapeutic efficacy of dapagliflozin on diabetic kidney disease in rats. Int Immunopharmacol 113:109272. https:\/\/doi.org\/10.1016\/j.intimp.2022.109272","journal-title":"Int Immunopharmacol"},{"key":"845_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108652","volume":"38","author":"C Yang","year":"2024","unstructured":"Yang C, Xiao C, Zhai X, Liu J, Yu M (2024a) SGLT2 inhibitor improves kidney function and morphology by regulating renal metabolism in mice with diabetic kidney disease. J Diabetes Complicat 38:108652. https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108652","journal-title":"J Diabetes Complicat"},{"key":"845_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2023.100613","volume":"47","author":"CC Yang","year":"2024","unstructured":"Yang CC, Chen YL, Sung PH, Chiang JY, Chen CH, Li YC, Yip HK (2024b) Repeated administration of adipose-derived mesenchymal stem cells added on beneficial effects of empagliflozin on protecting renal function in diabetic kidney disease rat. Biom J 47:100613. https:\/\/doi.org\/10.1016\/j.bj.2023.100613","journal-title":"Biom J"},{"key":"845_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2024.111308","volume":"122","author":"K Yang","year":"2024","unstructured":"Yang K, Liang W, Hu H, Zhang Z, Hao Y, Song Z, Yang L, Hu J, Chen Z, Ding G (2024c) ESRRA modulation by empagliflozin mitigates diabetic tubular injury via mitochondrial restoration. Cell Signal 122:111308. https:\/\/doi.org\/10.1016\/j.cellsig.2024.111308","journal-title":"Cell Signal"},{"key":"845_CR169","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.907984","volume":"13","author":"T Ye","year":"2022","unstructured":"Ye T, Zhang J, Wu D, Shi J, Kuang Z, Ma Y, Xu Q, Chen B, Kan C, Sun X, Han F (2022) Empagliflozin attenuates obesity-related kidney dysfunction and NLRP3 inflammasome activity through the HO-1-adiponectin axis. Front Endocrinol (Lausanne) 13:907984. https:\/\/doi.org\/10.3389\/fendo.2022.907984","journal-title":"Front Endocrinol (Lausanne)"},{"key":"845_CR170","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11255-024-04172-9","volume":"57","author":"YY Ye","year":"2025","unstructured":"Ye YY, Chen Y, Yang J, Wu J, Wang P (2025) Dapagliflozin restores autophagy and attenuates apoptosis via the AMPK\/mTOR pathway in diabetic nephropathy rats and high glucose-induced HK-2 cells. Int Urol Nephrol 57:249\u2013261. https:\/\/doi.org\/10.1007\/s11255-024-04172-9","journal-title":"Int Urol Nephrol"},{"key":"845_CR171","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1177\/1074248418763808","volume":"23","author":"FM Younis","year":"2018","unstructured":"Younis FM, Leor J, Abassi Z, Landa N, Hollander KS, Naftali-Shani N, Rosenthal T (2018) Beneficial effect of the SGLT2 inhibitor empagliflozin on glucose homeostasis and cardiovascular parameters in the Cohen Rosenthal Diabetic Hypertensive (CRDH) rat. J Cardiovasc Pharmacol Ther 23:358\u2013371. https:\/\/doi.org\/10.1177\/1074248418763808","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"845_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175560","volume":"943","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, Sun M, Jin Z, Zheng C, Ye H, Weng H (2023) Dapagliflozin ameliorates diabetic renal injury through suppressing the self-perpetuating cycle of inflammation mediated by HMGB1 feedback signaling in the kidney. Eur J Pharmacol 943:175560. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175560","journal-title":"Eur J Pharmacol"},{"key":"845_CR173","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2147\/dmso.S289712","volume":"14","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Ni L, Zhang L, Zha D, Hu C, Zhang L, Feng H, Wei X, Wu X (2021) Empagliflozin regulates the AdipoR1\/p-AMPK\/p-ACC pathway to alleviate lipid deposition in diabetic nephropathy. Diabetes Metab Syndr Obes 14:227\u2013240. https:\/\/doi.org\/10.2147\/dmso.S289712","journal-title":"Diabetes Metab Syndr Obes"},{"key":"845_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111785","volume":"131","author":"ZW Zhang","year":"2024","unstructured":"Zhang ZW, Tang MQ, Liu W, Song Y, Gao MJ, Ni P, Zhang DD, Mo QG, Zhao BQ (2024) Dapagliflozin prevents kidney podocytes pyroptosis via miR-155-5p\/HO-1\/NLRP3 axis modulation. Int Immunopharmacol 131:111785. https:\/\/doi.org\/10.1016\/j.intimp.2024.111785","journal-title":"Int Immunopharmacol"},{"key":"845_CR175","doi-asserted-by":"publisher","first-page":"7117","DOI":"10.1038\/s41598-025-91278-4","volume":"15","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Li L, Dai Y, Lian Y, Song H, Dai X, Su R, Yin J, Gu R (2025) Dapagliflozin inhibits ferroptosis and ameliorates renal fibrosis in diabetic C57BL\/6J mice. Sci Rep 15:7117. https:\/\/doi.org\/10.1038\/s41598-025-91278-4","journal-title":"Sci Rep"},{"key":"845_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.152999","volume":"793","author":"J Zhao","year":"2025","unstructured":"Zhao J, Dong C, Qiu P, Lv X, Zhang D, Zhao P, Ma B, Liu J, Chen W (2025) The effect of Dapagliflozin on diabetic nephropathy through PRMT1-SIRT1-FoxO1 pathway-mediated autophagy. Biochem Biophys Res Commun 793:152999. https:\/\/doi.org\/10.1016\/j.bbrc.2025.152999","journal-title":"Biochem Biophys Res Commun"},{"key":"845_CR177","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.848310","volume":"13","author":"C Zheng","year":"2022","unstructured":"Zheng C, Xuan W, Chen Z, Zhang R, Huang X, Zhu Y, Ma S, Chen K, Chen L, He M, Lin H, Liao W, Bin J, Liao Y (2022) CX3CL1 worsens cardiorenal dysfunction and serves as a therapeutic target of canagliflozin for cardiorenal syndrome. Front Pharmacol 13:848310. https:\/\/doi.org\/10.3389\/fphar.2022.848310","journal-title":"Front Pharmacol"},{"key":"845_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2025.112038","volume":"135","author":"T Zheng","year":"2025","unstructured":"Zheng T, Luo L, Wang X, Deng X, Xue M (2025) Canagliflozin ameliorates diabetic podocyte damage via enriching mitochondria-associated endoplasmic reticulum membranes. Cell Signal 135:112038. https:\/\/doi.org\/10.1016\/j.cellsig.2025.112038","journal-title":"Cell Signal"},{"key":"845_CR179","doi-asserted-by":"publisher","first-page":"221","DOI":"10.4196\/kjpp.2023.27.3.221","volume":"27","author":"Q Zhu","year":"2023","unstructured":"Zhu Q, Zhou Q, Luo XL, Zhang XJ, Li SY (2023) Combination of canagliflozin and puerarin alleviates the lipotoxicity to diabetic kidney in mice. Korean J Physiol Pharmacol 27:221\u2013230. https:\/\/doi.org\/10.4196\/kjpp.2023.27.3.221","journal-title":"Korean J Physiol Pharmacol"},{"key":"845_CR180","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE (2015) Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"845_CR181","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.741087","volume":"12","author":"M Zou","year":"2021","unstructured":"Zou M, Chen Y, Zheng Z, Sheng S, Jia Y, Wang X, Ren S, Yang Y, Li X, Dong W, Guan M, Zhang Q, Xue Y (2021) High-salt attenuates the efficacy of dapagliflozin in tubular protection by impairing fatty acid metabolism in diabetic kidney disease. Front Pharmacol 12:741087. https:\/\/doi.org\/10.3389\/fphar.2021.741087","journal-title":"Front Pharmacol"}],"container-title":["Handbook of Experimental Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2026_845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:58:55Z","timestamp":1790362735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2026_845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":181,"URL":"https:\/\/doi.org\/10.1007\/164_2026_845","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"12 August 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"The work in the authors\u2019 lab on SGLT2 inhibitors was supported by grants from the Deutsche Forschungsgemeinschaft (Mi 294-10\/1; to MCM) and T\u00dcBITAK (T\u00dcBITAK-SBAG 118S443 and 119S769; to EIA). AA received a stipend from Deutscher Akademischer Austauschdienst.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MCM is a consultant to Boehringer Ingelheim, a company marketing empagliflozin.The other authors do not report a conflict of interest.","order":2,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}